News | November 10, 2023
SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Diofan Ultra736 provides ultra-high water vapor barrier with excellent thermoformability, unlocking the potential to design thinner and more sustainable blister films
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
Reinforces Henkel commitment to supporting customers and ecosystem in medical healthcare
Fillauer recently announced the launch of the first-ever bio-attributed prosthetic foot shell
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Subscribe To Our Newsletter & Stay Updated
